FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.
If you are a woman living with advanced hereditary breast cancer please take our metastatic breast cancer survey and help us advocate for more options for treating hereditary breast cancer.
The cancer drug Avastin has been studied as a treatment for advanced breast and ovarian cancer. Not all women with advanced cancer respond equally to the medication. The FDA has decided that the benefits of Avastin do not outweigh the risks for women with advanced breast cancer and the agency has removed Avastin from the list of approved breast cancer therapies. While FORCE respects the FDA's decision, we are disappointed with this outcome. There are women with advanced breast cancer for whom Avastin appears to work well. FORCE has prepared a statement in response to the FDA recent ruling.
More research is needed to better determine which portion of breast cancer patients most benefit from Avastin. The decision of whether or not a woman with stage IV breast cancer should have access to Avastin should be made after discussion and consideration of benefits vs. risks with her health care team.